title: Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives.
abstract: Prostate cancer represents a third of all newly diagnosed cancers in men in the USA with an estimated incidence of 192,280 cases and 27,360 deaths in 2009. It continues to be a major cause of cancer-related morbidity and mortality, and there is an urgent need for new treatments. Historically, systemic therapy options were limited after progression on docetaxel-based chemotherapy. This article reviews current data on the novel therapeutics demonstrating activity in metastatic castration-resistant prostate cancer and their future role in the treatment of this disease with a poor prognosis.
authors.affiliation: Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA. kiran.lassi@gmail.com
authors.forename: Kiran
authors.initials: K
authors.lastname: Lassi
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Dawson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002369:Castration; D055808:Drug Discovery; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents